0001209191-19-056408.txt : 20191113 0001209191-19-056408.hdr.sgml : 20191113 20191113165932 ACCESSION NUMBER: 0001209191-19-056408 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191108 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Daniel Lee CENTRAL INDEX KEY: 0001713712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191214705 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-08 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Common Stock 2019-11-08 4 M 0 9742 1.89 A 34242 D Common Stock 2019-11-08 4 S 0 9742 48.00 D 24500 D Common Stock 2019-11-11 4 M 0 143185 1.89 A 167685 D Common Stock 2019-11-11 4 S 0 143185 48.0139 D 24500 D Common Stock 66779 I By Daniel L. Flynn Irrevocable Trust Common Stock 55270 I By Biochenomix, LLC Stock Option (Right to Buy) 1.89 2019-11-08 4 M 0 9742 0.00 D 2025-12-17 Common Stock 9742 310009 D Stock Option (Right to Buy) 1.89 2019-11-11 4 M 0 143185 0.00 D 2025-12-17 Common Stock 143185 166824 D The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.04, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. /s/ Thomas P. Kelly, Attorney-in-Fact 2019-11-13